NCT02511691

Brief Summary

Based on PET (18-PSS232) and MRI, glutamate release after N-acetylcystein challenge will be monitored in human brains.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for phase_2 healthy

Timeline
Completed

Started Jul 2015

Shorter than P25 for phase_2 healthy

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2015

Completed
22 days until next milestone

First Submitted

Initial submission to the registry

July 23, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 30, 2015

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 3, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 3, 2016

Completed
Last Updated

August 12, 2020

Status Verified

August 1, 2020

Enrollment Period

8 months

First QC Date

July 23, 2015

Last Update Submit

August 9, 2020

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

  • Difference of Binding Potentials of 18F-PSS232 in different brain regions between Baseline PET and PET after medical challenge

    for details, please see Innis: Journal of Cerebral Blood Flow \& Metabolism (2007) 27, 1533-1539

    Baseline PET and PET after medical challenge will be scanned within 3 months

Study Arms (1)

18F-PSS232

OTHER

Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein

Drug: 18F-PSS232

Interventions

18F-PSS232DRUG

Diagnostic PET Tracer

Also known as: 18FABP
18F-PSS232

Eligibility Criteria

Age20 Years - 75 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • healthy volunteer

You may not qualify if:

  • smoker
  • drug addiction
  • significant neurological or psychiatric conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hopsital Zurich

Zurich, 8091, Switzerland

Location

MeSH Terms

Interventions

PSS232

Study Officials

  • Alfred Buck, Prof. Dr.

    University of Zurich

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 23, 2015

First Posted

July 30, 2015

Study Start

July 1, 2015

Primary Completion

March 3, 2016

Study Completion

March 3, 2016

Last Updated

August 12, 2020

Record last verified: 2020-08

Locations

CH(1)